Pembrolizumab in HER2-Positive Gastric Cancer

Janjigian, Yelena; Kawazoe, Akihito; Bai, Yuxian; Xu, Jianming; Lonardi, Sara; Metges, Jean; Yanez, Patricio; Wyrwicz, Lucjan; Shen, Lin; Ostapenko, Yuriy; Bilici, Mehmet; Chung, Hyun; Shitara, Kohei; Qin, Shukui; Van Cutsem, Eric; Tabernero, Josep; Luo, Suxia; Mahave, Mauricio; Tang, Yong; Lowery, Maeve; Monteiro, Maria; Xu, Linzhi; Shih, Chie-Schin; Sharan, Kanu; Bhagia, Pooja; Rha, Sun

doi:10.1056/nejmc2408121

Pembrolizumab in HER2-Positive Gastric Cancer

Janjigian Y. Y., Kawazoe A., Bai Y., Xu J., Lonardi S., Metges J. P., ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, 2024 (SCI-Expanded)

Yayın Türü: Makale / Kısa Makale
Basım Tarihi: 2024
Doi Numarası: 10.1056/nejmc2408121
Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
Atatürk Üniversitesi Adresli: Evet

Özet

Pembrolizumab in HER2-Positive Gastric Cancer The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and chemotherapy alone.